GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (OTCPK:AKESF) » Definitions » Valuation Rank

Akeso (AKESF) Valuation Rank


View and export this data going back to 2021. Start your Free Trial

What is Akeso Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Akeso Valuation Rank Related Terms

Thank you for viewing the detailed overview of Akeso's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Akeso Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (OTCPK:AKESF) » Definitions » Valuation Rank
Comparable Companies
HKSE:01177 HKSE:06990 HKSE:01801 HKSE:01530 HKSE:01877 HKSE:01548 HKSE:02269 HKSE:09995 HKSE:09969 HKSE:02696 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
09926:Hong Kong 4RY:Germany
Address
6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437
Website
https://www.akesobio.com
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in USA.